nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0976	0.17	CbGbCtD
Temsirolimus—CYP3A7—Progesterone—uterine cancer	0.0976	0.17	CbGbCtD
Temsirolimus—CYP3A5—Progesterone—uterine cancer	0.0732	0.128	CbGbCtD
Temsirolimus—ABCB1—Progesterone—uterine cancer	0.0477	0.083	CbGbCtD
Temsirolimus—CYP2D6—Progesterone—uterine cancer	0.0449	0.0782	CbGbCtD
Temsirolimus—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0431	0.0751	CbGbCtD
Temsirolimus—ABCB1—Dactinomycin—uterine cancer	0.0378	0.0658	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—uterine cancer	0.0328	0.0571	CbGbCtD
Temsirolimus—CYP3A4—Progesterone—uterine cancer	0.0286	0.0497	CbGbCtD
Temsirolimus—ABCB1—Etoposide—uterine cancer	0.0213	0.0371	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—uterine cancer	0.0145	0.0253	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—uterine cancer	0.0137	0.0239	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—uterine cancer	0.0128	0.0223	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—uterine cancer	0.00872	0.0152	CbGbCtD
Temsirolimus—MTOR—myometrium—uterine cancer	0.00315	0.0532	CbGeAlD
Temsirolimus—FKBP1A—myometrium—uterine cancer	0.00284	0.0478	CbGeAlD
Temsirolimus—MTOR—epithelium—uterine cancer	0.00248	0.0418	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—uterine cancer	0.00238	0.0402	CbGeAlD
Temsirolimus—MTOR—renal system—uterine cancer	0.0023	0.0387	CbGeAlD
Temsirolimus—FKBP1A—epithelium—uterine cancer	0.00223	0.0376	CbGeAlD
Temsirolimus—MTOR—endometrium—uterine cancer	0.00222	0.0374	CbGeAlD
Temsirolimus—FKBP1A—uterine cervix—uterine cancer	0.00221	0.0372	CbGeAlD
Temsirolimus—MTOR—mammalian vulva—uterine cancer	0.00215	0.0362	CbGeAlD
Temsirolimus—FKBP1A—smooth muscle tissue—uterine cancer	0.00215	0.0362	CbGeAlD
Temsirolimus—FKBP1A—decidua—uterine cancer	0.0021	0.0355	CbGeAlD
Temsirolimus—FKBP1A—renal system—uterine cancer	0.00206	0.0348	CbGeAlD
Temsirolimus—MTOR—uterus—uterine cancer	0.00205	0.0345	CbGeAlD
Temsirolimus—FKBP1A—endometrium—uterine cancer	0.002	0.0337	CbGeAlD
Temsirolimus—FKBP1A—mammalian vulva—uterine cancer	0.00193	0.0326	CbGeAlD
Temsirolimus—FKBP1A—uterus—uterine cancer	0.00184	0.031	CbGeAlD
Temsirolimus—MTOR—female reproductive system—uterine cancer	0.00184	0.031	CbGeAlD
Temsirolimus—MTOR—female gonad—uterine cancer	0.00167	0.0282	CbGeAlD
Temsirolimus—MTOR—vagina—uterine cancer	0.00166	0.0281	CbGeAlD
Temsirolimus—FKBP1A—female reproductive system—uterine cancer	0.00165	0.0279	CbGeAlD
Temsirolimus—FKBP1A—female gonad—uterine cancer	0.0015	0.0254	CbGeAlD
Temsirolimus—FKBP1A—vagina—uterine cancer	0.0015	0.0252	CbGeAlD
Temsirolimus—MTOR—lymph node—uterine cancer	0.00108	0.0181	CbGeAlD
Temsirolimus—FKBP1A—lymph node—uterine cancer	0.000967	0.0163	CbGeAlD
Temsirolimus—CYP3A5—uterine cervix—uterine cancer	0.000961	0.0162	CbGeAlD
Temsirolimus—CYP3A5—renal system—uterine cancer	0.000899	0.0152	CbGeAlD
Temsirolimus—CYP3A4—renal system—uterine cancer	0.000675	0.0114	CbGeAlD
Temsirolimus—CYP2D6—renal system—uterine cancer	0.000664	0.0112	CbGeAlD
Temsirolimus—ABCB1—myometrium—uterine cancer	0.000656	0.0111	CbGeAlD
Temsirolimus—CYP3A5—female gonad—uterine cancer	0.000655	0.0111	CbGeAlD
Temsirolimus—CYP3A5—vagina—uterine cancer	0.000651	0.011	CbGeAlD
Temsirolimus—CYP3A4—female reproductive system—uterine cancer	0.00054	0.00912	CbGeAlD
Temsirolimus—CYP2D6—female reproductive system—uterine cancer	0.000532	0.00897	CbGeAlD
Temsirolimus—ABCB1—epithelium—uterine cancer	0.000515	0.00869	CbGeAlD
Temsirolimus—ABCB1—uterine cervix—uterine cancer	0.000511	0.00861	CbGeAlD
Temsirolimus—ABCB1—decidua—uterine cancer	0.000486	0.00821	CbGeAlD
Temsirolimus—CYP2D6—female gonad—uterine cancer	0.000484	0.00816	CbGeAlD
Temsirolimus—ABCB1—renal system—uterine cancer	0.000478	0.00806	CbGeAlD
Temsirolimus—ABCB1—endometrium—uterine cancer	0.000462	0.00779	CbGeAlD
Temsirolimus—ABCB1—mammalian vulva—uterine cancer	0.000447	0.00754	CbGeAlD
Temsirolimus—ABCB1—uterus—uterine cancer	0.000426	0.00718	CbGeAlD
Temsirolimus—ABCB1—female reproductive system—uterine cancer	0.000383	0.00645	CbGeAlD
Temsirolimus—ABCB1—female gonad—uterine cancer	0.000348	0.00587	CbGeAlD
Temsirolimus—ABCB1—vagina—uterine cancer	0.000346	0.00584	CbGeAlD
Temsirolimus—Dizziness—Progesterone—uterine cancer	0.000265	0.00107	CcSEcCtD
Temsirolimus—Angiopathy—Etoposide—uterine cancer	0.000262	0.00106	CcSEcCtD
Temsirolimus—Immune system disorder—Etoposide—uterine cancer	0.000261	0.00105	CcSEcCtD
Temsirolimus—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000261	0.00105	CcSEcCtD
Temsirolimus—Eczema—Epirubicin—uterine cancer	0.00026	0.00105	CcSEcCtD
Temsirolimus—Mediastinal disorder—Etoposide—uterine cancer	0.00026	0.00105	CcSEcCtD
Temsirolimus—Chills—Etoposide—uterine cancer	0.000259	0.00105	CcSEcCtD
Temsirolimus—Sepsis—Doxorubicin—uterine cancer	0.000259	0.00105	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000258	0.00104	CcSEcCtD
Temsirolimus—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.00104	CcSEcCtD
Temsirolimus—Vomiting—Progesterone—uterine cancer	0.000255	0.00103	CcSEcCtD
Temsirolimus—Rash—Progesterone—uterine cancer	0.000253	0.00102	CcSEcCtD
Temsirolimus—Dermatitis—Progesterone—uterine cancer	0.000253	0.00102	CcSEcCtD
Temsirolimus—Headache—Progesterone—uterine cancer	0.000251	0.00102	CcSEcCtD
Temsirolimus—Thrombophlebitis—Doxorubicin—uterine cancer	0.00025	0.00101	CcSEcCtD
Temsirolimus—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000249	0.00101	CcSEcCtD
Temsirolimus—Diabetes mellitus—Doxorubicin—uterine cancer	0.000249	0.00101	CcSEcCtD
Temsirolimus—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000249	0.001	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000248	0.001	CcSEcCtD
Temsirolimus—Decreased appetite—Dactinomycin—uterine cancer	0.000246	0.000996	CcSEcCtD
Temsirolimus—Dysgeusia—Etoposide—uterine cancer	0.000246	0.000995	CcSEcCtD
Temsirolimus—Dermatitis bullous—Epirubicin—uterine cancer	0.000245	0.000989	CcSEcCtD
Temsirolimus—Fatigue—Dactinomycin—uterine cancer	0.000244	0.000987	CcSEcCtD
Temsirolimus—Back pain—Etoposide—uterine cancer	0.000243	0.000982	CcSEcCtD
Temsirolimus—Pain—Dactinomycin—uterine cancer	0.000242	0.000979	CcSEcCtD
Temsirolimus—Eczema—Doxorubicin—uterine cancer	0.000241	0.000973	CcSEcCtD
Temsirolimus—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00024	0.000971	CcSEcCtD
Temsirolimus—Nausea—Progesterone—uterine cancer	0.000238	0.000962	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000234	0.000945	CcSEcCtD
Temsirolimus—Anaemia—Etoposide—uterine cancer	0.000232	0.000939	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000232	0.000937	CcSEcCtD
Temsirolimus—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000231	0.000934	CcSEcCtD
Temsirolimus—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.00023	0.000927	CcSEcCtD
Temsirolimus—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.000926	CcSEcCtD
Temsirolimus—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000229	0.000925	CcSEcCtD
Temsirolimus—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000228	0.00092	CcSEcCtD
Temsirolimus—Dermatitis bullous—Doxorubicin—uterine cancer	0.000227	0.000915	CcSEcCtD
Temsirolimus—Face oedema—Epirubicin—uterine cancer	0.000226	0.000913	CcSEcCtD
Temsirolimus—Leukopenia—Etoposide—uterine cancer	0.000225	0.000909	CcSEcCtD
Temsirolimus—Abdominal pain—Dactinomycin—uterine cancer	0.000224	0.000905	CcSEcCtD
Temsirolimus—Body temperature increased—Dactinomycin—uterine cancer	0.000224	0.000905	CcSEcCtD
Temsirolimus—ABCB1—lymph node—uterine cancer	0.000224	0.00378	CbGeAlD
Temsirolimus—Cough—Etoposide—uterine cancer	0.000219	0.000886	CcSEcCtD
Temsirolimus—Blood creatinine increased—Epirubicin—uterine cancer	0.000219	0.000886	CcSEcCtD
Temsirolimus—Convulsion—Etoposide—uterine cancer	0.000218	0.00088	CcSEcCtD
Temsirolimus—Dehydration—Epirubicin—uterine cancer	0.000218	0.000879	CcSEcCtD
Temsirolimus—Hypertension—Etoposide—uterine cancer	0.000217	0.000877	CcSEcCtD
Temsirolimus—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000217	0.000875	CcSEcCtD
Temsirolimus—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000216	0.000872	CcSEcCtD
Temsirolimus—Dry skin—Epirubicin—uterine cancer	0.000215	0.000867	CcSEcCtD
Temsirolimus—Chest pain—Etoposide—uterine cancer	0.000214	0.000865	CcSEcCtD
Temsirolimus—Hypokalaemia—Epirubicin—uterine cancer	0.000213	0.00086	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000213	0.000859	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000211	0.000851	CcSEcCtD
Temsirolimus—Face oedema—Doxorubicin—uterine cancer	0.000209	0.000844	CcSEcCtD
Temsirolimus—Hypersensitivity—Dactinomycin—uterine cancer	0.000209	0.000844	CcSEcCtD
Temsirolimus—Gastritis—Epirubicin—uterine cancer	0.000207	0.000837	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000206	0.000834	CcSEcCtD
Temsirolimus—Anaphylactic shock—Etoposide—uterine cancer	0.000205	0.000829	CcSEcCtD
Temsirolimus—Infection—Etoposide—uterine cancer	0.000204	0.000823	CcSEcCtD
Temsirolimus—Abdominal distension—Epirubicin—uterine cancer	0.000204	0.000823	CcSEcCtD
Temsirolimus—Asthenia—Dactinomycin—uterine cancer	0.000203	0.000822	CcSEcCtD
Temsirolimus—Blood creatinine increased—Doxorubicin—uterine cancer	0.000203	0.000819	CcSEcCtD
Temsirolimus—Dysphagia—Epirubicin—uterine cancer	0.000202	0.000817	CcSEcCtD
Temsirolimus—Influenza—Epirubicin—uterine cancer	0.000202	0.000817	CcSEcCtD
Temsirolimus—Dehydration—Doxorubicin—uterine cancer	0.000201	0.000813	CcSEcCtD
Temsirolimus—Thrombocytopenia—Etoposide—uterine cancer	0.000201	0.000812	CcSEcCtD
Temsirolimus—Skin disorder—Etoposide—uterine cancer	0.000199	0.000805	CcSEcCtD
Temsirolimus—Dry skin—Doxorubicin—uterine cancer	0.000199	0.000802	CcSEcCtD
Temsirolimus—Hypokalaemia—Doxorubicin—uterine cancer	0.000197	0.000796	CcSEcCtD
Temsirolimus—Anorexia—Etoposide—uterine cancer	0.000196	0.00079	CcSEcCtD
Temsirolimus—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000195	0.000788	CcSEcCtD
Temsirolimus—Bronchitis—Epirubicin—uterine cancer	0.000195	0.000786	CcSEcCtD
Temsirolimus—Diarrhoea—Dactinomycin—uterine cancer	0.000194	0.000784	CcSEcCtD
Temsirolimus—Gastritis—Doxorubicin—uterine cancer	0.000192	0.000774	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000191	0.000771	CcSEcCtD
Temsirolimus—Neutropenia—Epirubicin—uterine cancer	0.000189	0.000764	CcSEcCtD
Temsirolimus—Dysuria—Epirubicin—uterine cancer	0.000189	0.000764	CcSEcCtD
Temsirolimus—Abdominal distension—Doxorubicin—uterine cancer	0.000188	0.000761	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000188	0.000759	CcSEcCtD
Temsirolimus—Influenza—Doxorubicin—uterine cancer	0.000187	0.000756	CcSEcCtD
Temsirolimus—Dysphagia—Doxorubicin—uterine cancer	0.000187	0.000756	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—uterine cancer	0.000187	0.000755	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—uterine cancer	0.000183	0.000739	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—uterine cancer	0.000183	0.000739	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—uterine cancer	0.000182	0.000737	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—uterine cancer	0.000182	0.000737	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—uterine cancer	0.000181	0.000733	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—uterine cancer	0.00018	0.000729	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—uterine cancer	0.00018	0.000729	CcSEcCtD
Temsirolimus—Vomiting—Dactinomycin—uterine cancer	0.00018	0.000728	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—uterine cancer	0.00018	0.000727	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000179	0.000722	CcSEcCtD
Temsirolimus—Rash—Dactinomycin—uterine cancer	0.000179	0.000722	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—uterine cancer	0.000178	0.000721	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—uterine cancer	0.000177	0.000716	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—uterine cancer	0.000177	0.000716	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—uterine cancer	0.000177	0.000715	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—uterine cancer	0.000176	0.00071	CcSEcCtD
Temsirolimus—Constipation—Etoposide—uterine cancer	0.000175	0.000709	CcSEcCtD
Temsirolimus—Pain—Etoposide—uterine cancer	0.000175	0.000709	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—uterine cancer	0.000175	0.000708	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—uterine cancer	0.000175	0.000708	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—uterine cancer	0.000175	0.000707	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—uterine cancer	0.000175	0.000707	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000174	0.000703	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—uterine cancer	0.000173	0.000698	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—uterine cancer	0.000172	0.000695	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—uterine cancer	0.00017	0.000687	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—uterine cancer	0.000169	0.000684	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—uterine cancer	0.000169	0.000683	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—uterine cancer	0.000169	0.000682	CcSEcCtD
Temsirolimus—Nausea—Dactinomycin—uterine cancer	0.000168	0.00068	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—uterine cancer	0.000168	0.000678	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—uterine cancer	0.000168	0.000678	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—uterine cancer	0.000167	0.000674	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—uterine cancer	0.000167	0.000674	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000165	0.000668	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—uterine cancer	0.000164	0.000663	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—uterine cancer	0.000163	0.000657	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—uterine cancer	0.000162	0.000656	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—uterine cancer	0.000162	0.000655	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—uterine cancer	0.000162	0.000655	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—uterine cancer	0.000162	0.000655	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—uterine cancer	0.000162	0.000655	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—uterine cancer	0.000161	0.000649	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—uterine cancer	0.00016	0.000646	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—uterine cancer	0.00016	0.000644	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—uterine cancer	0.000159	0.000643	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—uterine cancer	0.000159	0.000643	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—uterine cancer	0.000159	0.000641	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—uterine cancer	0.000157	0.000636	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—uterine cancer	0.000157	0.000632	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—uterine cancer	0.000153	0.000618	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—uterine cancer	0.000151	0.000611	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—uterine cancer	0.000151	0.000611	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—uterine cancer	0.00015	0.000607	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—uterine cancer	0.00015	0.000607	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—uterine cancer	0.000149	0.000601	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—uterine cancer	0.000148	0.000598	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—uterine cancer	0.000148	0.000596	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—uterine cancer	0.000147	0.000595	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—uterine cancer	0.000147	0.000595	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—uterine cancer	0.000147	0.000593	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—uterine cancer	0.000147	0.000593	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—uterine cancer	0.000146	0.000591	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—uterine cancer	0.000146	0.000589	CcSEcCtD
Temsirolimus—Chills—Epirubicin—uterine cancer	0.000145	0.000587	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—uterine cancer	0.000145	0.000586	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—uterine cancer	0.000142	0.000573	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—uterine cancer	0.000142	0.000572	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—uterine cancer	0.000141	0.000569	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—uterine cancer	0.000141	0.000569	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—uterine cancer	0.00014	0.000567	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—uterine cancer	0.00014	0.000566	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—uterine cancer	0.000139	0.000562	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—uterine cancer	0.000138	0.000558	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—uterine cancer	0.000136	0.000551	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—uterine cancer	0.000136	0.000549	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—uterine cancer	0.000136	0.000548	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—uterine cancer	0.000135	0.000547	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—uterine cancer	0.000135	0.000545	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—uterine cancer	0.000134	0.000543	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—uterine cancer	0.000131	0.00053	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—uterine cancer	0.00013	0.000527	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—uterine cancer	0.00013	0.000527	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—uterine cancer	0.00013	0.000527	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—uterine cancer	0.00013	0.000526	CcSEcCtD
Temsirolimus—Rash—Etoposide—uterine cancer	0.000129	0.000523	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—uterine cancer	0.000129	0.000522	CcSEcCtD
Temsirolimus—Headache—Etoposide—uterine cancer	0.000129	0.000519	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—uterine cancer	0.000128	0.000516	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—uterine cancer	0.000126	0.00051	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—uterine cancer	0.000126	0.00051	CcSEcCtD
Temsirolimus—Cough—Epirubicin—uterine cancer	0.000123	0.000497	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—uterine cancer	0.000122	0.000493	CcSEcCtD
Temsirolimus—Nausea—Etoposide—uterine cancer	0.000122	0.000492	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—uterine cancer	0.000122	0.000492	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—uterine cancer	0.000121	0.000487	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—uterine cancer	0.00012	0.000485	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—uterine cancer	0.00012	0.000485	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—uterine cancer	0.00012	0.000485	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—uterine cancer	0.00012	0.000483	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000119	0.000481	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—uterine cancer	0.000117	0.000472	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—uterine cancer	0.000115	0.000465	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—uterine cancer	0.000115	0.000465	CcSEcCtD
Temsirolimus—Infection—Epirubicin—uterine cancer	0.000114	0.000462	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—uterine cancer	0.000114	0.00046	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—uterine cancer	0.000113	0.000456	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—uterine cancer	0.000113	0.000456	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—uterine cancer	0.000113	0.000455	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—uterine cancer	0.000113	0.000455	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—uterine cancer	0.000112	0.000451	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—uterine cancer	0.000111	0.000448	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—uterine cancer	0.000111	0.000448	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—uterine cancer	0.000111	0.000448	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—uterine cancer	0.000111	0.000447	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00011	0.000445	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—uterine cancer	0.00011	0.000443	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—uterine cancer	0.000106	0.00043	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—uterine cancer	0.000106	0.00043	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—uterine cancer	0.000106	0.000427	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000105	0.000423	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—uterine cancer	0.000104	0.000422	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—uterine cancer	0.000104	0.000421	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—uterine cancer	0.000104	0.00042	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—uterine cancer	0.000103	0.000418	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—uterine cancer	0.000103	0.000414	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—uterine cancer	0.000102	0.000413	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—uterine cancer	0.000101	0.00041	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—uterine cancer	0.0001	0.000404	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—uterine cancer	9.93e-05	0.000401	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—uterine cancer	9.92e-05	0.000401	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—uterine cancer	9.84e-05	0.000397	CcSEcCtD
Temsirolimus—Pain—Epirubicin—uterine cancer	9.84e-05	0.000397	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—uterine cancer	9.7e-05	0.000392	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—uterine cancer	9.63e-05	0.000389	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—uterine cancer	9.49e-05	0.000383	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—uterine cancer	9.46e-05	0.000382	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—uterine cancer	9.41e-05	0.00038	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—uterine cancer	9.25e-05	0.000374	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—uterine cancer	9.19e-05	0.000371	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—uterine cancer	9.18e-05	0.000371	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—uterine cancer	9.1e-05	0.000368	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—uterine cancer	9.1e-05	0.000368	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—uterine cancer	9.09e-05	0.000367	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—uterine cancer	9.09e-05	0.000367	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—uterine cancer	8.7e-05	0.000352	CcSEcCtD
Temsirolimus—Hypersensitivity—Epirubicin—uterine cancer	8.48e-05	0.000342	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—uterine cancer	8.41e-05	0.00034	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—uterine cancer	8.41e-05	0.00034	CcSEcCtD
Temsirolimus—Asthenia—Epirubicin—uterine cancer	8.25e-05	0.000333	CcSEcCtD
Temsirolimus—Pruritus—Epirubicin—uterine cancer	8.14e-05	0.000329	CcSEcCtD
Temsirolimus—Diarrhoea—Epirubicin—uterine cancer	7.87e-05	0.000318	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—uterine cancer	7.84e-05	0.000317	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—uterine cancer	7.64e-05	0.000308	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—uterine cancer	7.61e-05	0.000307	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—uterine cancer	7.53e-05	0.000304	CcSEcCtD
Temsirolimus—Vomiting—Epirubicin—uterine cancer	7.31e-05	0.000295	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—uterine cancer	7.28e-05	0.000294	CcSEcCtD
Temsirolimus—Rash—Epirubicin—uterine cancer	7.25e-05	0.000293	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—uterine cancer	7.25e-05	0.000293	CcSEcCtD
Temsirolimus—Headache—Epirubicin—uterine cancer	7.21e-05	0.000291	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—uterine cancer	7.04e-05	0.000284	CcSEcCtD
Temsirolimus—Nausea—Epirubicin—uterine cancer	6.83e-05	0.000276	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—uterine cancer	6.77e-05	0.000273	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—uterine cancer	6.71e-05	0.000271	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—uterine cancer	6.7e-05	0.000271	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—uterine cancer	6.67e-05	0.000269	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—uterine cancer	6.32e-05	0.000255	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB2—HRAS—uterine cancer	6.02e-05	0.000507	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FGFR2—uterine cancer	6.02e-05	0.000507	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—HRAS—uterine cancer	5.99e-05	0.000505	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FGFR2—uterine cancer	5.99e-05	0.000505	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—uterine cancer	5.98e-05	0.000504	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—EP300—uterine cancer	5.98e-05	0.000504	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—AKT1—uterine cancer	5.97e-05	0.000503	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IRF1—uterine cancer	5.97e-05	0.000503	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—PIK3CA—uterine cancer	5.96e-05	0.000502	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—uterine cancer	5.91e-05	0.000497	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PTEN—uterine cancer	5.88e-05	0.000495	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	5.87e-05	0.000495	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—AKT1—uterine cancer	5.87e-05	0.000494	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MTHFR—uterine cancer	5.77e-05	0.000486	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—uterine cancer	5.71e-05	0.000481	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—VEGFA—uterine cancer	5.67e-05	0.000477	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	5.65e-05	0.000476	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—PIK3CA—uterine cancer	5.64e-05	0.000475	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—HRAS—uterine cancer	5.64e-05	0.000475	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—uterine cancer	5.64e-05	0.000475	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—HRAS—uterine cancer	5.64e-05	0.000475	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—AKT1—uterine cancer	5.62e-05	0.000473	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	5.61e-05	0.000472	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—INHBA—uterine cancer	5.6e-05	0.000471	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	5.59e-05	0.000471	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—HRAS—uterine cancer	5.59e-05	0.00047	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKR1C3—uterine cancer	5.54e-05	0.000467	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—HRAS—uterine cancer	5.54e-05	0.000466	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	5.53e-05	0.000466	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—HRAS—uterine cancer	5.51e-05	0.000464	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HMGA1—uterine cancer	5.4e-05	0.000455	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	5.4e-05	0.000454	CbGpPWpGaD
Temsirolimus—MTOR—Insulin Signaling—AKT1—uterine cancer	5.4e-05	0.000454	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STK11—uterine cancer	5.37e-05	0.000453	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—AKT1—uterine cancer	5.37e-05	0.000452	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FBXW7—uterine cancer	5.35e-05	0.00045	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	5.34e-05	0.00045	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—AKT1—uterine cancer	5.34e-05	0.00045	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—AKT1—uterine cancer	5.32e-05	0.000448	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—AKT1—uterine cancer	5.29e-05	0.000445	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NRAS—uterine cancer	5.25e-05	0.000442	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—HRAS—uterine cancer	5.22e-05	0.000439	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—uterine cancer	5.21e-05	0.000439	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—POLD1—uterine cancer	5.09e-05	0.000428	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKR1C1—uterine cancer	5.04e-05	0.000424	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SOCS3—uterine cancer	5.03e-05	0.000424	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	4.99e-05	0.00042	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	4.98e-05	0.000419	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—AKT1—uterine cancer	4.98e-05	0.000419	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—AKT1—uterine cancer	4.98e-05	0.000419	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FBXW7—uterine cancer	4.94e-05	0.000416	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—AKT1—uterine cancer	4.93e-05	0.000415	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SRD5A2—uterine cancer	4.89e-05	0.000412	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NDUFB11—uterine cancer	4.89e-05	0.000412	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—uterine cancer	4.89e-05	0.000412	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—AKT1—uterine cancer	4.87e-05	0.00041	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN2B—uterine cancer	4.82e-05	0.000406	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKR1C1—uterine cancer	4.76e-05	0.000401	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	4.72e-05	0.000397	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKR1B1—uterine cancer	4.69e-05	0.000395	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—STAR—uterine cancer	4.69e-05	0.000395	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IGF1R—uterine cancer	4.68e-05	0.000394	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NDUFB11—uterine cancer	4.61e-05	0.000388	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SRD5A2—uterine cancer	4.61e-05	0.000388	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—AKT1—uterine cancer	4.61e-05	0.000388	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—uterine cancer	4.52e-05	0.00038	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDH1—uterine cancer	4.48e-05	0.000377	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	4.41e-05	0.000371	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SMAD3—uterine cancer	4.4e-05	0.00037	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—SOCS3—uterine cancer	4.38e-05	0.000369	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—uterine cancer	4.28e-05	0.00036	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—RRM2—uterine cancer	4.24e-05	0.000357	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FGFR2—uterine cancer	4.2e-05	0.000353	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—PIK3CA—uterine cancer	4.15e-05	0.00035	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—DCN—uterine cancer	4.12e-05	0.000347	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	4.1e-05	0.000345	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—uterine cancer	3.94e-05	0.000331	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKR1C3—uterine cancer	3.88e-05	0.000327	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP11A1—uterine cancer	3.88e-05	0.000327	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN2B—uterine cancer	3.87e-05	0.000326	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—uterine cancer	3.84e-05	0.000323	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.8e-05	0.00032	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PGR—uterine cancer	3.78e-05	0.000318	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—uterine cancer	3.78e-05	0.000318	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—uterine cancer	3.76e-05	0.000317	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—POLD1—uterine cancer	3.68e-05	0.00031	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKR1C3—uterine cancer	3.66e-05	0.000308	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FGFR2—uterine cancer	3.65e-05	0.000307	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CDKN1B—uterine cancer	3.64e-05	0.000307	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—YWHAE—uterine cancer	3.61e-05	0.000304	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ESR1—uterine cancer	3.59e-05	0.000302	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.59e-05	0.000302	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKR1B1—uterine cancer	3.54e-05	0.000298	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—STAR—uterine cancer	3.54e-05	0.000298	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SMAD3—uterine cancer	3.53e-05	0.000298	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDKN1B—uterine cancer	3.5e-05	0.000295	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.5e-05	0.000295	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CDKN1B—uterine cancer	3.48e-05	0.000293	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FBXW7—uterine cancer	3.46e-05	0.000291	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CTNNB1—uterine cancer	3.44e-05	0.00029	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKR1C1—uterine cancer	3.44e-05	0.00029	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKT1—uterine cancer	3.39e-05	0.000286	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FGFR2—uterine cancer	3.37e-05	0.000284	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—uterine cancer	3.36e-05	0.000283	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	3.34e-05	0.000281	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKR1B1—uterine cancer	3.33e-05	0.000281	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—STAR—uterine cancer	3.33e-05	0.000281	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CTNNB1—uterine cancer	3.29e-05	0.000277	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MTHFR—uterine cancer	3.24e-05	0.000273	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—uterine cancer	3.22e-05	0.000271	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—uterine cancer	3.21e-05	0.00027	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EP300—uterine cancer	3.2e-05	0.000269	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCL2—uterine cancer	3.16e-05	0.000266	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.16e-05	0.000266	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—RRM2—uterine cancer	3.07e-05	0.000258	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EP300—uterine cancer	3.06e-05	0.000258	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STK11—uterine cancer	3.02e-05	0.000255	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.01e-05	0.000254	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.01e-05	0.000254	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NRAS—uterine cancer	2.99e-05	0.000252	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—DCN—uterine cancer	2.98e-05	0.000251	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NRAS—uterine cancer	2.87e-05	0.000242	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NRAS—uterine cancer	2.86e-05	0.000241	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—STK11—uterine cancer	2.85e-05	0.00024	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CYP19A1—uterine cancer	2.85e-05	0.00024	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SOCS3—uterine cancer	2.83e-05	0.000238	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP11A1—uterine cancer	2.8e-05	0.000236	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—POLD1—uterine cancer	2.77e-05	0.000234	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDH1—uterine cancer	2.72e-05	0.000229	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN2B—uterine cancer	2.71e-05	0.000228	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.69e-05	0.000226	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKR1C3—uterine cancer	2.65e-05	0.000223	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—uterine cancer	2.63e-05	0.000222	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1R—uterine cancer	2.63e-05	0.000222	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—POLD1—uterine cancer	2.61e-05	0.00022	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKR1C1—uterine cancer	2.59e-05	0.000219	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—uterine cancer	2.58e-05	0.000217	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCL8—uterine cancer	2.5e-05	0.00021	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—uterine cancer	2.47e-05	0.000208	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SMAD3—uterine cancer	2.47e-05	0.000208	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.47e-05	0.000208	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—uterine cancer	2.46e-05	0.000207	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKR1C1—uterine cancer	2.45e-05	0.000206	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1B—uterine cancer	2.44e-05	0.000205	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.39e-05	0.000201	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PIK3CA—uterine cancer	2.37e-05	0.000199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGFR2—uterine cancer	2.36e-05	0.000199	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—RRM2—uterine cancer	2.31e-05	0.000195	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—uterine cancer	2.31e-05	0.000194	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—uterine cancer	2.29e-05	0.000193	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PIK3CA—uterine cancer	2.27e-05	0.000191	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PIK3CA—uterine cancer	2.26e-05	0.000191	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—uterine cancer	2.25e-05	0.000189	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—DCN—uterine cancer	2.25e-05	0.000189	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—uterine cancer	2.19e-05	0.000184	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—RRM2—uterine cancer	2.18e-05	0.000184	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.18e-05	0.000183	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—STAR—uterine cancer	2.18e-05	0.000183	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—MTHFR—uterine cancer	2.14e-05	0.000181	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EP300—uterine cancer	2.14e-05	0.00018	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1B—uterine cancer	2.12e-05	0.000179	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—uterine cancer	2.12e-05	0.000178	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—DCN—uterine cancer	2.12e-05	0.000178	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP11A1—uterine cancer	2.12e-05	0.000178	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—uterine cancer	2.1e-05	0.000177	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—uterine cancer	2.09e-05	0.000176	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP19A1—uterine cancer	2.06e-05	0.000174	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—STK11—uterine cancer	2.06e-05	0.000174	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—uterine cancer	2.03e-05	0.000171	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ESR1—uterine cancer	2.02e-05	0.00017	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.02e-05	0.00017	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—uterine cancer	2.01e-05	0.000169	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NRAS—uterine cancer	2e-05	0.000169	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKR1C3—uterine cancer	2e-05	0.000168	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.99e-05	0.000168	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1B—uterine cancer	1.96e-05	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—uterine cancer	1.95e-05	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—AKT1—uterine cancer	1.93e-05	0.000163	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.88e-05	0.000159	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EP300—uterine cancer	1.86e-05	0.000157	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—AKT1—uterine cancer	1.86e-05	0.000156	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—uterine cancer	1.85e-05	0.000156	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—AKT1—uterine cancer	1.85e-05	0.000156	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—uterine cancer	1.8e-05	0.000152	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCL2—uterine cancer	1.78e-05	0.00015	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NRAS—uterine cancer	1.74e-05	0.000147	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—uterine cancer	1.73e-05	0.000145	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EP300—uterine cancer	1.72e-05	0.000145	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—POLD1—uterine cancer	1.71e-05	0.000144	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NRAS—uterine cancer	1.61e-05	0.000136	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.6e-05	0.000135	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PIK3CA—uterine cancer	1.59e-05	0.000133	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—STK11—uterine cancer	1.56e-05	0.000131	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP19A1—uterine cancer	1.56e-05	0.000131	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MTHFR—uterine cancer	1.55e-05	0.000131	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—uterine cancer	1.53e-05	0.000129	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—uterine cancer	1.5e-05	0.000126	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—uterine cancer	1.48e-05	0.000125	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—STK11—uterine cancer	1.47e-05	0.000123	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.47e-05	0.000123	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—uterine cancer	1.47e-05	0.000123	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—RRM2—uterine cancer	1.42e-05	0.00012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—uterine cancer	1.41e-05	0.000118	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—uterine cancer	1.39e-05	0.000117	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—DCN—uterine cancer	1.38e-05	0.000116	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PIK3CA—uterine cancer	1.38e-05	0.000116	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1B—uterine cancer	1.37e-05	0.000116	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.3e-05	0.00011	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—uterine cancer	1.3e-05	0.000109	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKT1—uterine cancer	1.29e-05	0.000109	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—uterine cancer	1.28e-05	0.000107	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PIK3CA—uterine cancer	1.27e-05	0.000107	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—uterine cancer	1.26e-05	0.000106	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.23e-05	0.000104	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EP300—uterine cancer	1.21e-05	0.000101	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—uterine cancer	1.19e-05	0.0001	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—uterine cancer	1.18e-05	9.92e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MTHFR—uterine cancer	1.17e-05	9.85e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—uterine cancer	1.14e-05	9.61e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—EP300—uterine cancer	1.14e-05	9.58e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NRAS—uterine cancer	1.13e-05	9.49e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—AKT1—uterine cancer	1.13e-05	9.48e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MTHFR—uterine cancer	1.1e-05	9.28e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—AKT1—uterine cancer	1.04e-05	8.76e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—uterine cancer	9.7e-06	8.17e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—STK11—uterine cancer	9.59e-06	8.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP19A1—uterine cancer	9.59e-06	8.07e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PIK3CA—uterine cancer	8.91e-06	7.51e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—uterine cancer	8.62e-06	7.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—uterine cancer	8.62e-06	7.26e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PIK3CA—uterine cancer	8.41e-06	7.09e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—uterine cancer	8.25e-06	6.95e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—EP300—uterine cancer	8.22e-06	6.92e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKT1—uterine cancer	7.28e-06	6.13e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTHFR—uterine cancer	7.21e-06	6.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—AKT1—uterine cancer	6.87e-06	5.79e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—uterine cancer	6.51e-06	5.48e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—EP300—uterine cancer	6.2e-06	5.22e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—uterine cancer	6.13e-06	5.16e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PIK3CA—uterine cancer	6.08e-06	5.12e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—EP300—uterine cancer	5.85e-06	4.92e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—AKT1—uterine cancer	4.97e-06	4.18e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PIK3CA—uterine cancer	4.59e-06	3.86e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PIK3CA—uterine cancer	4.33e-06	3.64e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—uterine cancer	4.01e-06	3.38e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—EP300—uterine cancer	3.82e-06	3.22e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—AKT1—uterine cancer	3.75e-06	3.16e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—AKT1—uterine cancer	3.53e-06	2.98e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.83e-06	2.38e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—AKT1—uterine cancer	2.31e-06	1.95e-05	CbGpPWpGaD
